TABLE 2.
Meta-analyses of statin benefits in COVID-19 cases.
| References | Main effect a | Comments |
|---|---|---|
| Gupta et al. (2021) | ↑ | Antecedent statin use was associated with inpatient mortality |
| Those on statins had lower C-reactive protein | ||
| Wu et al. (2021) | ↑ | Statin use showed a reduction in mortality (29%↓) and a need for invasive mechanical ventilators (19%↓) |
| Yetmar et al. (2021) | ↑ | Prior statin use was associated with a lower risk of mortality or severity in patients with COVID-19 |
| Severity is defined by advanced ventilator support, ICU admission, acute respiratory distress syndrome (ARDS) | ||
| Zein et al. (2022) | ↑ | Statin was associated with a lower risk of mortality (28%↓) This association was not affected by age, male gender, diabetes and hypertension |
| Chow et al. (2021) | ↑ | Patients given statin de novo after COVID-19 diagnosis were at a lower risk for mortality |
| Among non-ICU patients, statin users were at a lower risk of mortality relative to non-statin users | ||
| Kollias et al. (2021) | ↑ | Statin therapy was associated with a lower risk of in-hospital mortality (35%↓) |
| 12 studies (65 years) with comorbidities—hypertension (66%), diabetes (43%), statin use (30%) | ||
| Kow and Hasan (2022) | ↑ | Statin was associated with a lower risk of all-cause mortality and severe illness in patients with COVID-19 |
| Gutierrez-Mariscal et al. (2021) | ↑ | Statin use was associated with a lower risk of mortality in patients with COVID-19 |
| Most common comorbidities—hypertension (51%) dyslipidemia (41%), diabetes (33%) | ||
| Only chronic use of statins reduced mortality in patients with COVID-19 | ||
| Ayeh et al. (2021) | ↓ | Statin use had no effect on COVID-19-related mortality |
| Statin use increased COVID-19-related severity by 18% | ||
| The divergent findings may be due to different demographics and prevalent comorbidities | ||
| Choi et al. (2022) | ↑ | Statin use was associated with a reduction in in-hospital mortality (21%↓) |
| Higher-intensity statin use had even more protection than low-to-medium statin use | ||
| Vahedian-Azimi et al. (2021) | ↑ | Antecedent statin use reduced tracheal intubation (27%↓) |
| Statin use after hospitalization was associated with 46%↓ mortality |
a
Meta-analysis studies with statins that improved (↑) and did not improve (↓) in patient severity and death.